OXiGENE plans to announce its first-quarter 2005 financial results on April 27, prior to the opening of the NASDAQ Stock Market.
To listen to a live or an archived version of the webcast, please log on to the Company's website, www.oxigene.com Under the "Investor Center" tab, click on the link to "Presentations & Conference Calls."
OXiGENE's first-quarter conference call also can be heard live by dialing 800-930-1344 (domestic) or 312-461-0644 (international) five minutes prior to the call. A replay will be available starting at 1:00 p.m. ET and ending at midnight ET, May 3rd. To access the replay, dial 888-203-1112 (domestic) or 719-457-0820 (international) and refer to reservation number 3653624.
About OXiGENE, Inc.
OXiGENE is an emerging pharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.
CONTACT: OXiGENE Inc.
James Murphy, 781-547-5900
Chris Erdman, 508-647-0209
SOURCE: OXiGENE Inc.